Eisai's Michael Irizarry on broadening Leqembi's use with its subcutaneous version, an ongoing Phase III trial in treating patients before dementia symptoms appear and news from a Phase II study of its tau-targeting asset, etalanetug.
Eisai's Michael Irizarry on broadening Leqembi's use with its subcutaneous version, an ongoing Phase III trial in treating patients before dementia symptoms appear and news from a Phase II study of its tau-targeting asset, etalanetug.